|
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression of phosphatidylinositol 3' -kinase (PI3K)/ protein kinase B (AKT) and c-Jun N-terminal kinase (JNK) was down-regulated by GEN (all P < .05) while reversed by HULC overexpression.HULC was up-regulated in GC.
|
30176223 |
2018 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Wnt/β-catenin and PI3K/Akt signaling pathways promote EMT in gastric cancer by epigenetic regulation via H3 lysine 27 acetylation.
|
28671020 |
2017 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, MGr1-Ag/37LRP may interact with PrP<sup>C</sup> and promote the PrP<sup>C</sup> induced multi-drug-resistance in gastric cancer through PI3K/AKT pathway.
|
29069734 |
2017 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
PKM2 promotes cell migration and inhibits autophagy by mediating PI3K/AKT activation and contributes to the malignant development of gastric cancer.
|
28588255 |
2017 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, knockdown of UBE2C using siRNA markedly reduced the level of phosphorylation AURKA (p‑AURKA) via Wnt/β‑catenin and PI3K/Akt signaling pathways suppressed the occurrence and development of gastric cancer.
|
28260026 |
2017 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Long non-coding RNA CRNDE is a novel tumor promoter by modulating PI3K/AKT signal pathways in human gastric cancer.
|
29243780 |
2017 |
|
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Dysregulated lncRNA-UCA1 contributes to the progression of gastric cancer through regulation of the PI3K-Akt-mTOR signaling pathway.
|
29212166 |
2017 |
|
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
LncRNA AK023391 promotes tumorigenesis and invasion of gastric cancer through activation of the PI3K/Akt signaling pathway.
|
29282102 |
2017 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study revealed that (1) PIK3CA hotspot mutations occurred with low frequency in gastric cancer; (2) PIK3CA hotspot mutations were not directly associated with PI3K pathway activation; and (3) p-AKT (+) may be a biomarker for better outcomes for gastric cancer patients undergoing gastrectomy regardless of the PIK3CA mutation status.
|
28550907 |
2017 |
|
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This study demonstrates, for the first time, that SHIP2 is frequently downregulated in gastric cancer, and reduced SHIP2 expression promotes tumorigenesis and proliferation of gastric cancer via activation of the PI3K/Akt signaling.
|
26201869 |
2016 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
AURKA induces EMT by regulating histone modification through Wnt/β-catenin and PI3K/Akt signaling pathway in gastric cancer.
|
27121204 |
2016 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Similar to human GC, pathway analyses identified WNT, TGF-β, and PI3K-PTEN signaling, ubiquitin-mediated proteolysis, adherens junctions, and RNA degradation in addition to genes involved in chromatin modification and organization as highly deregulated pathways in GC.
|
27006499 |
2016 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
This is the first time this extensive panel of 9 genes within PI3K/AKT/mTOR pathway has been studied in GC to clarify the biological role of this pathway in GC and develop new strategies for this malignancy.
|
27156070 |
2016 |
|
Malignant neoplasm of stomach
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutations in PI3K/AKT pathway genes were associated with hematogenous metastasis in patients with diffuse-type gastric cancer.
|
26701847 |
2016 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
CXCL10/CXCR3 axis promotes the invasion of gastric cancer via PI3K/AKT pathway-dependent MMPs production.
|
27470388 |
2016 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Knockdown of Rap1b Enhances Apoptosis and Autophagy in Gastric Cancer Cells via the PI3K/Akt/mTOR Pathway.
|
27712585 |
2016 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent studies on the genomic landscape of gastric adenocarcinoma have identified several key signaling molecules, including epidermal growth factor receptor family (ErbB) members, vascular endothelial growth factor receptor family (VEGFR) members and PI3K/Akt/mTOR pathway components, that have been implicated in the molecular pathogenesis of gastric cancers.
|
26398764 |
2015 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
In summary, our results suggest that Fra-1 is upregulated in gastric cancer tissues and plays its function by affecting the PI3K/Akt and p53 signaling pathway in gastric cancer.
|
26330014 |
2015 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
MiR-19a promotes epithelial-mesenchymal transition through PI3K/AKT pathway in gastric cancer.
|
25914465 |
2015 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
The HER-2 positive SGC-7901 secreted more transforming growth factor beta 1 (TGF-β1) and resultantly activated MMP-9 to enhance s-ICAM-1 secretion and further studies showed that phosphatidylinositol-3 kinase (PI3K)/Akt/NF-κB signaling pathway was involved in GC pathogenesis.
|
25613482 |
2015 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Celecoxib sensitizes gastric cancer to rapamycin via inhibition of the Cbl-b-regulated PI3K/Akt pathway.
|
25701378 |
2015 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ultimately, PI3K p110α represents a novel target for gastric cancer.
|
26543351 |
2015 |
|
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Hepatocyte growth factor (HGF) upregulates heparanase expression via the PI3K/Akt/NF-κB signaling pathway for gastric cancer metastasis.
|
25727320 |
2015 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Herein, we review the common dysregulation of PI3K/Akt/mTOR pathway in GC and the various types of single or dual pathway inhibitors under development that might have a superior role in GC treatment.
|
26604635 |
2015 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, this CagA- PI3K/AKT-Sp1-RBP2-Cyclin D1 pathway may serve as a novel mechanism for gastric epithelial cell malignant transformation and then gastric cancer (GC).
|
25015565 |
2014 |